L'Oréal US settles first hair relaxer cancer trial in Chicago
Four women who blamed chemical hair straighteners for their cancers settled with L'Oréal's US arm and other makers mid-trial. The deal is confidential, the science is still debated, and over 12,700 similar cases are waiting.

Straight, sleek hair has been a beauty ideal for decades, and plenty of us have sat in a salon chair while chemicals did the work. That's why a courtroom in Chicago is worth paying attention to. The first trial over claims that hair relaxers cause cancer has ended before reaching a verdict, with a settlement.
Four women who said years of using chemical hair straighteners gave them gynaecological cancers settled on Monday with L'Oréal's US subsidiary and other product makers, their lawyers said, according to Reuters. The amount is confidential. The women had sued in Cook County, Illinois, in 2023 and 2024, and theirs were the first such cases to go to trial, which began with jury selection on November 9.
This is far bigger than four cases. More than 12,700 lawsuits have been grouped before a federal judge in Chicago, Reuters reports, citing court records, and some others are in state courts. The products involved include brands such as Dark and Lovely and Optimum, which were widely marketed to Black women in the US. Separately, the US states of Arizona and Minnesota sued L'Oréal this year, alleging it misled women about the products' safety.
L'Oréal hasn't admitted anything. A spokesperson told Reuters the company "strictly follows all regulations in every market in which it operates", and said it remains confident in the safety of its SoftSheen-Carson products, including relaxers. A settlement also doesn't settle the science: it simply means these four cases won't produce a jury verdict.
So what does the research actually say? Much of the litigation followed a 2022 study by the US National Institutes of Health. Researchers followed 33,497 American women aged 35 to 74 for almost 11 years, during which 378 developed uterine cancer. Women who reported using straighteners more than four times in the previous year had an estimated 4.05% risk of uterine cancer by age 70, against 1.64% for women who never used them. "This doubling rate is concerning," the lead researcher said in the NIH release.
But there are important caveats, and the NIH spelled them out. The study didn't record brands or ingredients, so it can't say which chemical might be responsible; researchers suggested candidates such as parabens, bisphenol A, metals and formaldehyde. It found no link with hair dyes, bleach, highlights or perms. The lead author also stressed that uterine cancer is relatively rare and that the findings need confirming in other populations. L'Oréal says the study did not establish that its products caused anyone's illness.
Is there a takeaway for salon-goers in India? Writing in The Week last month, Dr Ajara Sayyad, medical director of Eterne Clinic in Mumbai's Powai, pointed to the same NIH study and cautioned that "This was an association, not proof of causation". She also noted a 2024 medical journal report of a young woman who suffered repeated kidney injury after salon straightening with a glyoxylic acid product, a reminder that "formaldehyde-free" labels aren't a full safety guarantee.
What happens next? The thousands of federal cases are still pending, as are the state lawsuits. Any future trial verdict, or a broader settlement, would be the next real signal. For now, nobody outside the deal knows what it cost.
Get the day's best stories on WhatsApp. Free, a few a day, no spam.
Follow on WhatsAppSource ledger · स्रोत खाता
Each fact in this story, where it came from, and how it was checked.
| Fact | Source | Check |
|---|---|---|
| Four women settled Monday (16 Nov) with L'Oréal's US subsidiary and other makers during Chicago trial | Claims Journal (Reuters copy, Diana Novak Jones) | Single source |
| Four women settled Monday (16 Nov) with L'Oréal's US subsidiary and other makers during Chicago trial | Devdiscourse (Reuters feed) | Single source |
| Four women settled Monday (16 Nov) with L'Oréal's US subsidiary and other makers during Chicago trial | Global Cosmetics News | Single source |
| Terms confidential | Claims Journal (Reuters copy, Diana Novak Jones) | Single source |
| Terms confidential | Devdiscourse (Reuters feed) | Single source |
| Terms confidential | Global Cosmetics News | Single source |
| Sued in Cook County in 2023 and 2024; first such cases to go to trial; jury selection began Nov 9 | Claims Journal (Reuters copy, Diana Novak Jones) | Single source |
| Sued in Cook County in 2023 and 2024; first such cases to go to trial; jury selection began Nov 9 | Devdiscourse (Reuters feed) | Single source |
| More than 12,700 cases centralised before a federal judge in Chicago (court records) | Claims Journal (Reuters copy, Diana Novak Jones) | Single source |
| More than 12,700 cases centralised before a federal judge in Chicago (court records) | Devdiscourse (Reuters feed) | Single source |
| More than 12,700 cases centralised before a federal judge in Chicago (court records) | Global Cosmetics News | Single source |
| Products include Dark and Lovely and Optimum, widely marketed to Black women | Claims Journal (Reuters copy, Diana Novak Jones) | Single source |
| Products include Dark and Lovely and Optimum, widely marketed to Black women | Devdiscourse (Reuters feed) | Single source |
| Arizona and Minnesota sued L'Oréal this year | Claims Journal (Reuters copy, Diana Novak Jones) | Single source |
| Arizona and Minnesota sued L'Oréal this year | Devdiscourse (Reuters feed) | Single source |
| Arizona and Minnesota sued L'Oréal this year | Global Cosmetics News | Single source |
| L'Oréal says study did not establish causation; confident in SoftSheen-Carson safety | Claims Journal (Reuters copy, Diana Novak Jones) | Single source |
| L'Oréal says study did not establish causation; confident in SoftSheen-Carson safety | Devdiscourse (Reuters feed) | Single source |
| NIH study: 33,497 women aged 35-74, almost 11 years, 378 uterine cancers, 4.05% vs 1.64% by age 70, frequent = >4 times in previous year | US National Institutes of Health | Confirmed, official source |
| No brand/ingredient data; possible chemicals parabens, BPA, metals, formaldehyde; no link with dyes, bleach, highlights, perms; uterine cancer relatively rare; needs confirmation | US National Institutes of Health | Confirmed, official source |
| Dr Sayyad's caution and the 2024 NEJM kidney-injury case (glyoxylic acid) | The Week | Single source |
Corrections to this story: none.